Autolus Therapeutics (AUTL) Operating Leases (2019 - 2025)

Autolus Therapeutics (AUTL) has 7 years of Operating Leases data on file, last reported at $71.4 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases rose 43.84% year-over-year to $71.4 million; the trailing twelve-month figure through Dec 2025 stood at $71.4 million (up 43.84% YoY), and the FY2025 full-year result was $71.4 million, up 43.84% from the prior year.
• Operating Leases for Q4 2025 stood at $71.4 million, up from $65.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $71.4 million in Q4 2025 and bottomed at $11.3 million in Q3 2022.
• The 5-year median for Operating Leases is $45.8 million (2023), against an average of $37.4 million.
• The widest annual swing landed in 2021, when Operating Leases slumped 67.28%; it then jumped 315.27% in 2023.
• A 5-year view of Operating Leases shows it stood at $16.5 million in 2021, then rose by 16.16% to $19.2 million in 2022, then jumped by 149.32% to $47.9 million in 2023, then increased by 3.58% to $49.6 million in 2024, then soared by 43.84% to $71.4 million in 2025.
• The last three Operating Leases figures came in at $71.4 million (Q4 2025), $65.8 million (Q3 2025), and $61.3 million (Q2 2025), per Business Quant data.

Peer Comparison